Diet plays a pivotal role in influencing autoimmune diseases like multiple sclerosis (MS), inflammatory bowel disease, and ...

Co. Ltd. and Viva Star Biosciences (US) Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, ...

Usnoflast (ZYIL1) is a novel, oral small molecule NLRP3 inhibitor. Usnoflast has been studied in several pre-clinical models of neuroinflammation, Parkinson’s disease, inflammatory bowel disease (IBD) ...

The NLRP3 inflammasome is implicated in a host ... in preclinical development but being eyed as a possible treatment for multiple sclerosis.

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

“We believe JOTROL’s ability to inhibit NLRP3, based on multiple published resveratrol trials, makes it an ideal candidate for diseases such as Parkinson’s and Alzheimer’s, and it ...

NLRP3 inhibition in the CNS may have therapeutic utility in a range of neurodegenerative diseases with high unmet medical need, including Alzheimer’s disease, multiple sclerosis, and amyotrophic ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...